PV Management Question 2
Transcript
The correct answer means that WBC over 12 remains significantly associated with thrombotic events. We come to the conclusion from this based on the results of the REVEAL study that showed that even hematocrit that would be controlled below 45%, which is currently a guide for patients being controlled. If they had persistent leukocytosis over 12, that remains significantly associated with risk for thrombosis. Although even white cell count over 11 was associated with approximately 2 times increased risk of thrombotic event compared with white cell count less than 11, this was not statistically significant. But a gain of 12 and above was significant, despite the hematocrit being below 45%.
References
- Marchetti M, Vannucchi AM, Griesshammer M, et al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol. 2022;9(4):e301-e311. doi:10.1016/S2352-3026(22)00046-1
- ELN 2021 guideline recommendations for polycythemia vera. MPN Hub. May 10, 2022. Accessed April 15, 2026. https://mpn-hub.com/medical-information/eln-2021-guideline-recommendations-for-polycythemia-vera
- Gerds AT, Mesa R, Burke JM, et al. Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL. Blood. 2024;143(16):1646-1655. doi:10.1182/blood.2023020232
- Grunwald MR, Burke JM, Kuter DJ, et al. Symptom burden and blood counts in patients with polycythemia vera in the United States: an analysis from the REVEAL study. Clin Lymphoma Myeloma Leuk. 2019;19(9):579-584.e1. doi:10.1016/j.clml.2019.06.001
© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
Dr Masarova is an associate professor in the Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. She is also co-leader of Myeloproliferative Neoplasms Session, Division of Cancer Medicine, at MD Anderson. Dr Masarova earned her medical degree from Comenius University Bratislava School of Medicine, Bratislava, Slovakia, and completed research and clinical fellowships in Leukemia at UT MD Anderson. While in Slovakia, Dr Masarova actively collaborated with researchers from other European sites to co-develop the largest Central European database of invasive fungal infections. She is a highly motivated physician, pursuing an academic, translational-research career while expanding her broad knowledge, training, and expertise in oncology and hematology. Her research includes various aspects of hematologic malignancies, with special interest in infections, immune system involvement, and influence of disease background and therapies on their outcome. Dr Masarova has completed many research projects and first-authored several manuscripts in peer-reviewed journals in addition to presenting her research at large Hematologic and Oncologic Conferences worldwide.
